TRIM30 Rabbit anti-Human, Mouse, Rat, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA520591
A suggested positive control is mouse heart tissue lysate. PA5-20591 can be used with blocking peptide PEP-0711.TRIM30 belongs to a family of the tripartite motif (TRIM) proteins involved in the regulation of cell proliferation, differentiation, development, oncogenesis, apoptosis and antiviral responses. The TRIM protein family is an expanding family of RING ( ft.really interesting new gene ft.) proteins, also known as RBCC proteins as they contain an RBCC motif, which comprises a RING domain, one or two B-boxes and a predicted coiled-coil region. Studies have shown that some TRIM family members are critical to innate immunity; TRIM5, TRIM19 and TRIM25, for example, have been shown to restrict viral infection. A recent study shows that TRIM30 functions as a negative modulator of the TLR signaling pathway, by targeting TAB2 and TAB3, and contributes to the inhibition of TLR-mediated NF-kappa-B activation. The importance of TRIM30 in the attenuation or termination of NF-kappa-B activation suggests that targeting of TAB2 and TAB3 by TRIM30alpha may be a mechanism for modulating many types of immune responses.
|A 24 amino acid peptide near the amino terminus of the mouse TRIM30.|
|Antigen affinity chromatography|
|Human, Mouse, Rat|
|Immunocytochemistry, Immunofluorescence, Immunohistochemistry, Western Blot|
|PBS with 0.02% sodium azide|
|Rpt-1, Rpt1, Trim30; down regulatory protein of interleukin-2 receptor; regulatory protein, T lymphocyte 1; tripartite motif protein 30; tripartite motif-containing 30; tripartite motif-containing protein 30|
|Maintain refrigerated at 2-8°C for up to 3 months. For long term storage store at -20°C|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok